Jefferies on Viridian Therapeutic (VRDN): 'Attractive 2026 Setup With Pot'l Launch and Pivotal Data', 'one of our Top Picks in 2026'
Tweet Send to a Friend
Jefferies analyst Kelly Shi reiterated a Buy rating and $44.00 price target on Viridian Therapeutic (NASDAQ: VRDN).The analyst comments "Following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
